CN112368293A - 活化剂 - Google Patents

活化剂 Download PDF

Info

Publication number
CN112368293A
CN112368293A CN201980043872.7A CN201980043872A CN112368293A CN 112368293 A CN112368293 A CN 112368293A CN 201980043872 A CN201980043872 A CN 201980043872A CN 112368293 A CN112368293 A CN 112368293A
Authority
CN
China
Prior art keywords
cells
peptide
cell
lck
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980043872.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·V·阿格雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intemet Therapeutics Ltd
Original Assignee
Intemet Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018901672A external-priority patent/AU2018901672A0/en
Application filed by Intemet Therapeutics Ltd filed Critical Intemet Therapeutics Ltd
Publication of CN112368293A publication Critical patent/CN112368293A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201980043872.7A 2018-05-15 2019-05-15 活化剂 Pending CN112368293A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901672A AU2018901672A0 (en) 2018-05-15 Activating Agents
AU2018901672 2018-05-15
PCT/AU2019/050462 WO2019218015A1 (en) 2018-05-15 2019-05-15 Activating agents

Publications (1)

Publication Number Publication Date
CN112368293A true CN112368293A (zh) 2021-02-12

Family

ID=68539125

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980043872.7A Pending CN112368293A (zh) 2018-05-15 2019-05-15 活化剂

Country Status (8)

Country Link
US (2) US12134663B2 (https=)
EP (1) EP3794015A4 (https=)
JP (1) JP7644000B2 (https=)
KR (1) KR20210021311A (https=)
CN (1) CN112368293A (https=)
AU (1) AU2019268411B2 (https=)
CA (1) CA3100072A1 (https=)
WO (1) WO2019218015A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166205A (zh) * 2018-11-30 2021-07-23 英特肽治疗有限公司 用于改善皮肤病状的多肽和方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912789B2 (en) 2018-05-15 2024-02-27 Interk Peptide Therapeutics Limited Peptide activating agent
EP4244234A4 (en) * 2020-11-10 2024-12-25 InterK Peptide Therapeutics Limited POLYPEPTIDES AND METHODS FOR IMPROVING SKIN DISEASES
JP2024532850A (ja) * 2021-08-20 2024-09-10 インテルク ペプチド セラピューティクス リミテッド がん及びがん療法に関連する自己免疫を含む、自己免疫を処置するための組成物及び方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214755A1 (en) * 2000-12-22 2005-09-29 Agrez Michael V Map kinase integrin-binding domain
US20100158968A1 (en) * 2008-12-10 2010-06-24 Alyssa Panitch Cell-permeant peptide-based inhibitor of kinases
WO2015053338A1 (ja) * 2013-10-08 2015-04-16 学校法人東京理科大学 カチオン性ペプチドおよびそれを含む医薬組成物
US20150110744A1 (en) * 2012-01-24 2015-04-23 Inter-K Pty Limited Peptide agents for cancer therapy
CN110997693A (zh) * 2017-06-07 2020-04-10 阿德克斯公司 τ聚集抑制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1226552B (it) * 1988-07-29 1991-01-24 Ellem Ind Farmaceutica Peptidi immunostimolanti.
US20030162956A1 (en) 1997-04-07 2003-08-28 Human Genome Sciences, Inc. Leukocyte regulatory factors 1 and 2
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
ATE541940T1 (de) 2001-10-15 2012-02-15 Engeneic Molecular Delivery Pty Ltd Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US7611885B2 (en) 2003-06-24 2009-11-03 Engeneic Molecular Delivery Pty, Ltd. Pharmaceutically compatible method for purifying intact bacterial minicells
JP2007522094A (ja) * 2003-09-22 2007-08-09 アシドフィル エルエルシー 小分子組成物、及びその組成物を使用して薬物効率を高めるための方法
US20060194319A1 (en) 2004-09-02 2006-08-31 Webb Carol F Promoter substitution for immunoglobulin therapy
WO2006029981A1 (en) 2004-09-13 2006-03-23 Vib Vzw Abin-mediated protection against lung inflammatory disease
DK2229956T3 (da) 2004-09-13 2013-07-29 Genzyme Corp Multimere konstruktioner
US7429481B2 (en) 2004-09-14 2008-09-30 University Of Pittsburgh Targeting viruses using a modified sindbis glycoprotein
WO2009021137A2 (en) * 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
CN101854945B (zh) * 2007-09-18 2015-07-01 株式会社绿多肽 Ctl诱导剂组合物
SI2119726T2 (en) * 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
WO2010094085A1 (en) * 2009-02-23 2010-08-26 Inter-K Pty Limited Inhibition of multiple cell activation pathways
WO2012033911A2 (en) * 2010-09-08 2012-03-15 The Johns Hopkins University Polyionic papilloma virus-like particle (vlp) vaccines
US20140186372A1 (en) * 2011-06-16 2014-07-03 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
WO2013033838A1 (en) 2011-09-09 2013-03-14 Pharmagap Inc. Liposomal formulations of cationic peptides and uses thereof
JP6367600B2 (ja) 2014-04-18 2018-08-01 矢崎総業株式会社 コネクタ

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214755A1 (en) * 2000-12-22 2005-09-29 Agrez Michael V Map kinase integrin-binding domain
US20100158968A1 (en) * 2008-12-10 2010-06-24 Alyssa Panitch Cell-permeant peptide-based inhibitor of kinases
US20150110744A1 (en) * 2012-01-24 2015-04-23 Inter-K Pty Limited Peptide agents for cancer therapy
WO2015053338A1 (ja) * 2013-10-08 2015-04-16 学校法人東京理科大学 カチオン性ペプチドおよびそれを含む医薬組成物
CN110997693A (zh) * 2017-06-07 2020-04-10 阿德克斯公司 τ聚集抑制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166205A (zh) * 2018-11-30 2021-07-23 英特肽治疗有限公司 用于改善皮肤病状的多肽和方法

Also Published As

Publication number Publication date
EP3794015A4 (en) 2022-03-30
JP7644000B2 (ja) 2025-03-11
EP3794015A1 (en) 2021-03-24
WO2019218015A1 (en) 2019-11-21
US20260103488A1 (en) 2026-04-16
US20210380639A1 (en) 2021-12-09
US12134663B2 (en) 2024-11-05
AU2019268411A1 (en) 2020-12-03
JP2021523945A (ja) 2021-09-09
KR20210021311A (ko) 2021-02-25
CA3100072A1 (en) 2019-11-21
AU2019268411B2 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
US20260103488A1 (en) Activating agents
ES2918501T3 (es) Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
JP2021521776A (ja) Ｍａｇｅ−ｂ２特異性を有するｔ細胞受容体およびその使用
US20250019397A1 (en) Peptide Activating Agent
ES2777227T3 (es) CD33 soluble para tratar síndromes mielodisplásicos (MDS)
JP7508478B2 (ja) ユビキチン化欠損キメラ抗原受容体及びその使用
EP3652203A1 (en) Engineered tsc2
KR20210117217A (ko) 제대혈 혈장 유래의 엑소좀 또는 이의 모방체 및 이의 면역억제 용도
US20240238419A1 (en) Method for constitutive malt1 protease activation
CN115151274B (zh) Hla限制性hormad1 t细胞受体及其用途
CA3184316C (fr) Complexe immunomodulateur et ses applications pour la therapie
Kujawa Development of small molecule immunomodulators of the human immune system for cancer therapy
WO2025247951A1 (en) Fyn kinase inhibitors, combinations and uses thereof
Mohan The role of LKB1 spliceoforms in iTreg-Th17 plasticity and their interactions with PKCθ and SIRT1 downstream of IL-6 signaling
남기리 The roles of T cell-intrinsic CD99 and myeloid cell-expressed IDO1 in T cell response
Park The Molecular Mechanism of RIPK1-Induced Cell Death And Its Impact On The Immune Response
Sarraf et al. Wnt5A supports antigen cross-presentation and CD8 T cell activation
KR20120112196A (ko) Ａｋｔ 음성 조절제로서의 Ｈａｄｅｓ의 용도
Tran Investigating factors that govern T cell and dendritic cell function as therapeutic strategies for immune therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination